A Phase 4 interventional study of Epinephrine in Cardiac Arrest, Out-Of-Hospital, Sudden Cardiac Arrest and Ventricular Fibrillation, sponsored by Unity Health Toronto. Recruiting at 9 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Unity Health Toronto · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada — 4 open to participants now, 6 under way, none of them phase 3. Out-of-Hospital Cardiac Arrest · Canada.
Among the 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 4, and was the 7th registered.
314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.
Browse Out-of-Hospital Cardiac Arrest studies →4 of the 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada are open now. Recruiting first, the newest first:
University of Calgary · Sites in Canada
University of Michigan · Sites in Canada, United States, Australia and 2 more countries
Ages 2 days–17 yrs
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,250 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.
Median enrollment 397 across the 14 interventional studies, 6,287 across the 2 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Unity Health Toronto is the lead sponsor of 447 studies on the registry; 81 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Unity Health Toronto has 1 study filed under Out-of-Hospital Cardiac Arrest — fewer than ten, so there is no comparison to draw.
1 of the studies in Out-of-Hospital Cardiac Arrest with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07829887University of CalgaryCerebral Oximetry in Management of Post Cardiac Arrest | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this randomized controlled trial is to evaluate whether a low cumulative dose of epinephrine ("low dose") is non-inferior to a standard cumulative dose of epinephrine ("standard dose") with respect to survival to hospital discharge among adults undergoing resuscitation for OHCA due to ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT).
This study is designed as a prospective, multicentre, single-blinded randomized controlled trial (RCT) where eligible OHCA patients are randomized to receive a low cumulative dose of epinephrine (low dose epinephrine, up to 2mg total) or a standard cumulative dose of epinephrine (standard dose epinephrine, up to 6mg total) in a 1:1 fashion.
Eligible OHCA patients will be treated by paramedics who will initiate cardiopulmonary resuscitation (CPR) and the delivery of defibrillation shocks per paramedic agencies' treatment protocols. After one defibrillation and when feasible, paramedics will establish peripheral intravenous (IV) access, and patients will be randomly allocated to either the low dose or standard dose treatment arm. Epinephrine doses (according to treatment assignment) will be administered every 3-5 minutes, based on current guidelines and paramedic protocols, until the first return of spontaneous circulation (ROSC) is achieved or if resuscitation has been terminated by the base hospital physician. Other medications (e.g. antiarrhythmics, magnesium, beta blockers) and interventions (e.g. intubation) may be interposed as required. Follow-up will take place using a combination of administrative databases (e.g. the Discharge Abstract Database and the National Ambulatory Care Reporting System) and telephone interviews.
This RCT will evaluate a fundamental change in the treatment of OHCA. The investigators hypothesize that a low cumulative dose of epinephrine will improve patient survival to hospital discharge compared to a standard cumulative dose of epinephrine. Please feel free to contact epidose@unityhealth.to for further information.
The criteria were revised on the registry on Oct 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Epinephrine up to 2mg total
Drug: Epinephrine
Epinephrine up to 6mg total
Drug: Epinephrine
Epinephrine 1mg 1:10000 (10cc) per dose
Also known as: Adrenaline
Survival to hospital discharge
Individuals discharged alive from hospital
Time frame: Through study completion (up to 5 years)
Return of spontaneous circulation in out-of-hospital setting
Return of spontaneous circulation in the field
Time frame: Through study completion (up to 5 years)
Survival to emergency department arrival
Individuals alive upon arrival to a hospital emergency department
Time frame: Through study completion (up to 5 years)
Survival to admission with death prior to discharge
Individuals alive upon hospital admission who die in-hospital before being discharged
Time frame: Through study completion (up to 5 years)
Survival to discharge outside of a long-term healthcare facility e.g. nursing home
Individuals discharged alive from hospital to a care facility
Time frame: Through study completion (up to 5 years)
Modified Rankin Scale (mRS) score
Assessment of neurological function, scores range from 0 to 6 where higher scores indicate worse neurological function (0=no symptoms, 6=dead)
Time frame: 12+/-3 months
Health Utility Index-3 (HUI-3) score
Assessment of quality of life, scores range from -0.36 to 1 where higher scores indicate better quality life (negative scores=a state worse than being dead, 0=dead, 1=perfect health)
Time frame: 12+/-3 months
Hospital Anxiety and Depression Scale score
Assessment of quality of life, scores range from 0 to 21 where higher scores indicate more anxiety/depression
Time frame: 12+/-3 months
Length of stay in hospital
Length of time an individual remained in-hospital (length in days)
Time frame: Through study completion (up to 5 years)
Length of stay in critical care unit
Length of time an individual remained in a crucial care unit (length in days)
Time frame: Through study completion (up to 5 years)
Survival post-arrest
Survival following hospital discharge, up to 5 years
Time frame: Up to 5 years
Recurrent cardiac arrest(s)
Number of cardiac arrests following the index arrest
Time frame: Up to 5 years
ICD implant post-arrest
Whether an implantable cardioverter defibrillator was implanted post-arrest
Time frame: Up to 5 years
Cardiovascular re-hospitalization(s)
Number of cardiovascular re-hospitalizations
Time frame: Up to 5 years
All-cause re-hospitalizations(s)
Number of re-hospitalizations for any reason
Time frame: Up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Dec 2028, 67 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Dec 2028, on Oct 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epinephrine
Out-of-Hospital Cardiac Arrest →